11 rue de MOLSHEIM, 67082
232 articles with Transgene SA
Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers
Transgene announced that detailed results of the data from the Phase 1b/2 trial combining TG4001, a HPV16 targeted therapeutic vaccine, with avelumab, a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies, will be presented in a poster presentation at the upcoming virtual meeting of the Society for Immunotherapy of Cancer taking place November 9-14, 2020.
Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting
Transgene, and BioInvent International AB announce that they will be presenting a poster on BT-001 at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.
BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
BioInvent International AB and Transgene announce that they will be presenting a poster on BT-001 at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
Transgene, NEC Corporation, and BostonGene Corporation announced a strategic collaboration for two ongoing Phase 1 clinical trials of TG4050, an individualized therapeutic vaccine for ovarian and head & neck cancers based on Transgene’s proprietary myvac® platform and NEC’s AI-driven Neoantigen Prediction System in Europe and the United States.
Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022
Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022 2020 Half-year results and business update TG4001: Very promising results from Phase 1b/2 trial in HPV-positive cancers TG6002: Initial translational results confirm the value of intravenous administration Preclinical and clinical projects progressing despite the Covid-19 pandemic €33.2 million of cash at the end of June 2020 wa
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that Management will participate in the upcoming investor events set out below.
Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that it has raised $22.2 million from the sale of 10.3 million shares of its minority stake in Tasly BioPharmaceuticals to a Chinese investment fund.
Transgene Reports Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers
Exploratory Phase 1b/2 trial targeting a heterogeneous population of patients with HPV16-positive, recurrent and/or metastatic cancer whose disease has progressed after up to three lines of chemotherapy, reports promising clinical activity with the combination regimen. Patient follow-up and translational analyses are ongoing. Full results will be presented at an upcoming scientific conference. Transgene intends to continue the
Transgene and Hypertrust Patient Data Care Announce Successful Go-Live of the World’s First Blockchain Solution for Clinical Trials of Personalized Healthcare
Transgene and Hypertrust Patient Data Care announced as a world premiere the first productive blockchain solution for clinical trials of personalized healthcare, leveraging the Hypertrust X-Chain for Clinical Trials product.
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene
Proof of concept for novel oncolytic virus with differentiated anti-CTLA4 antibody Significant antitumor activity of BT-001 seen in several immunocompetent models Treatment with BT-001 also induced a specific and long-lasting immune memory, which is thought to act on distant tumors and to prevent potential relapse Phase I clinical trial with BT-001 expected to start before the end of 2020 Data presented at AACR Virtual
Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, presents its broad viral vector expertise and their potential to transform the fight against cancer at the AACR 2020 Virtual Annual Meeting II. myvac ® Transgene presents data demonstrating that the prediction algorithm used to customize TG4050 for each patient i
The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held at 10:00 a.m. at the Company's headquarters chaired by Philippe Archinard, Chairman and CEO, to approve the company financial statements for the year ended December 31, 2019 and to vote the others resolutions submitted to their approval.
Transgene and NEC Demonstrate High Accuracy of AI-Based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050
T G4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene’s proprietary myvac® platform with NEC’s cutting-edge Artificial Intelligence (AI) capabilities to select patient-specific neoantigens
Transgene and BioInvent Present Preclinical Data Demonstrating BT-001’s Powerful Activity Against Solid Tumors
Transgene and BioInvent International AB announce new highly promising preclinical data demonstrating the broad therapeutic potential of BT-001, an anti-CTLA4 antibody-encoding oncolytic virus, against solid tumors.
Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses
Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s proprietary DuckCelt®-T17 cell line.
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, publishes its financial results for 2019 and provides an update on its product portfolio.
3/5/2020Life sciences companies from across the globe provide updates on their businesses and pipelines.
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
Oncolytic Virus Design and Preclinical Data to be Presented at ESMO TAT, IO Summit Europe, Keystone Symposium and AACR 2020
BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
Oncolytic virus design and preclinical data to be presented at ESMO TAT, IO Summit Europe, Keystone Symposium and AACR 2020